ADAP
Price
$1.06
Change
-$0.02 (-1.85%)
Updated
Apr 25, 6:59 PM EST
10 days until earnings call
CYTK
Price
$64.80
Change
-$2.02 (-3.02%)
Updated
Apr 25, 6:59 PM EST
6 days until earnings call
Ad is loading...

Analysis and predictions ADAP vs CYTK

Header iconADAP vs CYTK Comparison
Open Charts ADAP vs CYTKBanner chart's image
Adaptimmune Therapeutics
Price$1.06
Change-$0.02 (-1.85%)
Volume$360.96K
CapitalizationN/A
Cytokinetics
Price$64.80
Change-$2.02 (-3.02%)
Volume$509.52K
CapitalizationN/A
View a ticker or compare two or three
ADAP vs CYTK Comparison Chart

Loading...

ADAPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ADAP vs. CYTK commentary
Apr 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a StrongSell and CYTK is a Hold.

COMPARISON
Comparison
Apr 26, 2024
Stock price -- (ADAP: $1.06 vs. CYTK: $64.80)
Brand notoriety: ADAP and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 34% vs. CYTK: 54%
Market capitalization -- ADAP: $270.9M vs. CYTK: $6.78B
ADAP [@Biotechnology] is valued at $270.9M. CYTK’s [@Biotechnology] market capitalization is $6.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $562.44B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 2 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 2 green, 3 red.
According to our system of comparison, CYTK is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 5 bearish.
  • CYTK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than CYTK.

Price Growth

ADAP (@Biotechnology) experienced а +17.99% price change this week, while CYTK (@Biotechnology) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.00%. For the same industry, the average monthly price growth was -2.94%, and the average quarterly price growth was +1264.32%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 07, 2024.

CYTK is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Biotechnology (+8.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ADAP with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($6.78B) has a higher market cap than ADAP($271M). ADAP YTD gains are higher at: 33.670 vs. CYTK (-22.386).
ADAPCYTKADAP / CYTK
Capitalization271M6.78B4%
EBITDAN/AN/A-
Gain YTD33.670-22.386-150%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ADAP vs CYTK: Fundamental Ratings
ADAP
CYTK
OUTLOOK RATING
1..100
5580
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
10022
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4441
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for CYTK (100). This means that ADAP’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for ADAP (100). This means that CYTK’s stock grew significantly faster than ADAP’s over the last 12 months.

ADAP's SMR Rating (99) in the Biotechnology industry is in the same range as CYTK (100). This means that ADAP’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (41) in the Biotechnology industry is in the same range as ADAP (44). This means that CYTK’s stock grew similarly to ADAP’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ADAP (100). This means that CYTK’s stock grew significantly faster than ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPCYTK
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend about 1 month ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ADAPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RFEU64.260.32
+0.50%
First Trust RiverFront Dynamic Eurp ETF
ULST40.400.02
+0.05%
SPDR® SSgA Ultra Short Term Bond ETF
SHYG41.96-0.07
-0.17%
iShares 0-5 Year High Yield Corp Bd ETF
NOCT47.18-0.10
-0.21%
Innovator Growth-100 Pwr Buff ETF™ Oct
IVVB26.85-0.12
-0.44%
iShares Large Cap Deep Buffer ETF

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with CRSP. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-1.85%
CRSP - ADAP
36%
Loosely correlated
-3.45%
ORMP - ADAP
36%
Loosely correlated
-2.95%
CYTK - ADAP
32%
Poorly correlated
-3.02%
AXON - ADAP
31%
Poorly correlated
+1.27%
ALT - ADAP
31%
Poorly correlated
+1.69%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with TVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-3.02%
TVTX - CYTK
57%
Loosely correlated
-1.10%
VBIV - CYTK
44%
Loosely correlated
+1.59%
BCAB - CYTK
44%
Loosely correlated
-4.26%
KRON - CYTK
43%
Loosely correlated
+2.08%
IOVA - CYTK
42%
Loosely correlated
-1.45%
More